Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
The company had incurred a loss of 6 cents per share in the year-ago quarter. The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti + Opfolda. Revenues in the reported quarter totaled $110.4 million, up 28% year over year on a reported and constant-currency (cc) basis. However, the figure missed the Zacks Consensus Estimate of $112 million. The top line comprised sales of Galafold, which is approved for Fabry disease and Pombiliti + Opfolda. The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease in September 2023. Shares of Amicus lost 6.5% on Mar 9, following the first-quarter earnings release. Year to date, shares of FOLD have plunged 33.2% compared with the industry's 6.3% decline. Image Source: Zacks Investment Research Quarter in Detail In the first quarter, Galafold net product sales were $99.
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $18.00 price target on the stock.MarketBeat
- Do Options Traders Know Something About Amicus (FOLD) Stock We Don't? [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics: Too Cheap At Under $10 A Share [Seeking Alpha]Seeking Alpha
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.MarketBeat
- Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 5/9/24 - Miss
FOLD
Sec Filings
- 6/3/24 - Form 144
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- FOLD's page on the SEC website